208 related articles for article (PubMed ID: 33630157)
1. Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer.
Wrona E; Potemski P; Sclafani F; Borowiec M
Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):2. PubMed ID: 33630157
[TBL] [Abstract][Full Text] [Related]
2. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
[TBL] [Abstract][Full Text] [Related]
3. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma.
Wang J; Karime C; Majeed U; Starr JS; Borad MJ; Babiker HM
Expert Opin Investig Drugs; 2023 May; 32(5):387-399. PubMed ID: 37092893
[TBL] [Abstract][Full Text] [Related]
4. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker.
Bressy C; Lac S; Nigri J; Leca J; Roques J; Lavaut MN; Secq V; Guillaumond F; Bui TT; Pietrasz D; Granjeaud S; Bachet JB; Ouaissi M; Iovanna J; Vasseur S; Tomasini R
Cancer Res; 2018 Feb; 78(4):909-921. PubMed ID: 29269518
[TBL] [Abstract][Full Text] [Related]
5. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of leukemia inhibitory factor in human pancreatic cancer].
Peng F; Zhou J; Sheng W; Zhang D; Dong M
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):90-5. PubMed ID: 24721346
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
9. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
10. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
11. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
14. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins.
Liot S; Balas J; Aubert A; Prigent L; Mercier-Gouy P; Verrier B; Bertolino P; Hennino A; Valcourt U; Lambert E
Front Immunol; 2021; 12():612271. PubMed ID: 33889150
[TBL] [Abstract][Full Text] [Related]
15. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
[TBL] [Abstract][Full Text] [Related]
16. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
[TBL] [Abstract][Full Text] [Related]
17. Aquaporins in pancreatic ductal adenocarcinoma.
Bruun-Sørensen AS; Edamana S; Login FH; Borgquist S; Nejsum LN
APMIS; 2021 Dec; 129(12):700-705. PubMed ID: 34582595
[TBL] [Abstract][Full Text] [Related]
18. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
19. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
20. Exploiting inflammation for therapeutic gain in pancreatic cancer.
Steele CW; Jamieson NB; Evans TR; McKay CJ; Sansom OJ; Morton JP; Carter CR
Br J Cancer; 2013 Mar; 108(5):997-1003. PubMed ID: 23385734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
